免疫性血小板减少性紫癜的发病机制与临床研究进展  

Advances in pathogenetic and clinical research of immune thrombocytopenic purpura

作　　者：王兆钺[1] 

机构地区：[1]苏州大学附属第一医院江苏省血液研究所,苏州215006

出　　处：《中国免疫学杂志》2009年第12期1141-1144,共4页Chinese Journal of Immunology

基　　金：国家自然科学基金(30770917)资助

摘　　要：免疫性血小板减少性紫癜(Immune thrombocytopenic purpura,ITP)是自身抗体介导的血小板减少综合征,自身抗原的主要成分是血小板一种或多种糖蛋白;细胞免疫也是血小板破坏的一个重要原因。目前ITP的诊断仍是临床排除性诊断,分为原发性与继发性两种。ITP治疗的目的是使患者血小板计数提高到安全水平。肾上腺糖皮质激素仍是ITP的首选药物,静脉输注丙种球蛋白(IVIg)用于控制严重出血与重度血小板减少,脾切除仍是治疗慢性ITP的主要手段。血小板生成素(TPO)类似物可能成为新的治疗方法。对成人慢性ITP患者应常规进行幽门螺杆菌(Hp)筛查,阳性患者应根除Hp。Immune thrombocytopenic purpura （ITP） is characterized by autoantibody-mediated thrombocytopenia, with the major autoanfigens being platelet glycoproteins. Cellular immunity is also involved in platelet destruction.ITP remains a diagnosis of exclusion, defined as primary and secondary ITP. The major goal for its treatment is to provide a safe platelet count. Cortieosteroid-based regimens are commonly used as the initial treatment, and severe patients have temporary responses to intravenous immunoglobulin. Splenenectomy shows curative-potential in some chronic ITP cases. Thrombopoiefie agents would become a new approach of treatment. Helicobacter pylori （ H. pylori） infection should be screened in adult chronic ITP, and when the result is positive, H. pylori eradication therapy is indicated.

关 键 词：免疫性血小板减少性紫癜 发病机制 治疗 血小板生成素 幽门螺杆菌 

分 类 号：R558[医药卫生—血液循环系统疾病]